Mountain Crest Acquisition Corp II

Better Therapeutics, Inc. develops software-based prescription digital therapeutics for treating diabetes, heart disease, and other cardiometabolic conditions. It engages in developing a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The company was founded by Kevin J. Appelbaum and David P. Perry in April 2015 and is headquartered in San Francisco, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. It offers software-based solutions for type 2 diabetes, heart disease and other conditions. The company was founded by Kevin J. Appelbaum and David P. Perry in April 2015 and is headquartered in San Francisco, CA.

NEW YORK--(BUSINESS WIRE)--Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.

Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024. Further, as previously disclosed, the Company's securities are subject to delisting from the Nasdaq Stock Market u.

Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its.

Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showca.

Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Biotricity

ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 2, at 7 p.m. Eastern Time (ET).

Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.

Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its novel Cognitive Behavioral Therapy (CBT) platform intended to treat adults with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. Breakthrough status is reserved for technol.

Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that it has entered into a rebate agreement with one of the nation's leading Pharmacy Benefit Managers (PBMs) negotiating on behalf of over 70 million lives in the US. The rebate agreement, effective January 1, 2024, applies to the PBM's commercial book of business and provides plan participants of the PB.

Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the publication of health economic data for its prescription-only digital behavioral treatment for type 2 diabetes (T2D), AspyreRx. The study, titled "Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes'' has been published in Advances in Therapy, a prominent peer-reviewed.

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

SAN FRANCISCO & PALO ALTO, Calif.--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc., a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and Glooko, Inc., a global leader in chronic condition management, today announced a partnership to integrate Better Therapeutics' AspyreRx™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko's diabetes management platform. This collaboration will enable healthcare providers in the United States who.

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for its novel PDT designed to treat metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NAFLD and NASH. MAS.

Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today disclosed several initiatives aimed at extending the company's cash runway sufficiently to demonstrate commercial traction with its lead product, AspyreRx. The company launched AspyreRx in October of this year, after receiving U.S. Food and Drug Administration (FDA) authorization in July for the treatment of adults wi.

Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has been awarded Frost & Sullivan's prestigious 2023 Best Practices Technology Innovation Leadership Award in the North American diabetes digital behavioral therapeutics industry. Frost & Sullivan's team of industry analysts conducted extensive research and in-depth interviews to evaluate multiple.

Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and CEO Diane Gomez-Thinnes - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Rahul Rakhit - LifeSci Capital Operator Good day and thank you for standing by. Welcome to the Better Therapeutics' Third Quarter 2023 Business Update Call.

Better Therapeutics, Inc. (BTTX) Q3 2023 Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the third quarter 2023 and provided an update on progress towards achieving key corporate milestones. "We made tremendous progress in Q3, which included the FDA authorization of AspyreRx and the completion of the work required for a commercial launch in early October. AspyreRx offers healthcare.

Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its third quarter 2023 financial results before the market opens on Thursday, November 09, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, November 09, 2023. To access the conference call, please register at: https://r.

Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023

Arcutis Biotherapeutics

Evelo Biosciences Inc

Heart Test Laboratories Inc

SINTX Technologies Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced its participation in the American College of Lifestyle Medicine's (ACLM) 2023 Lifestyle Medicine Annual Conference (LM2023), to be held October 29 to November 1, 2023, in Denver, Colorado. The conference brings together medical professionals, including physicians, healthcare executives, academic faculty, and.

Better Therapeutics to Participate in the American College of Lifestyle Medicine's 2023 Annual Conference

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced the commercial launch of AspyreRx, the first cognitive behavioral therapy (CBT) app to receive U.S Food and Drug Administration (FDA) authorization as a Class II device to treat adults with type 2 diabetes (T2D). AspyreRx is a prescription-only therapy, backed by a randomized controlled trial (RCT) that demo.

Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced top-line findings from a recent subgroup analysis of AspyreRx (formerly BT-001) in its pivotal trial for type 2 diabetes (T2D). The analysis reveals that adjunctive use of AspyreRx with standard of care, including GLP-1 receptor agonists (GLP-1), leads to a substantially greater clinical improvement compared.

Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced the pre-print publication of the LivVita study's results in Gastro Hep Advances, a peer reviewed journal produced by the American Gastroenterological Association (AGA). The study successfully met its primary endpoint by reducing liver fat within 90 days, while also achieving key secondary endpoints related t.

Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has completed the enrollment of 1,000 participants across two studies as part of its ongoing clinical program to evaluate the long-term effectiveness of AspyreRxTM (formerly BT-001). AspyreRx received FDA authorization in July 2023 as the first PDT to deliver Cognitive Behavioral Therapy (CBT) to treat ad.

Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Keay Nakae - Chardan Rahul Rakhit - LifeSci Capital Operator Good day and thank you for standing by, and welcome to the Better Therapeutics' Second Quarter 2023 Update Call. At this time all participants are in a listen-only mode.

Better Therapeutics, Inc. (BTTX) Q2 2023 Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the second quarter 2023 and provided an update on progress towards achieving key corporate milestones. “Obtaining FDA authorization for AspyreRx was a pivotal milestone for our company and a catalyst for strengthening our financial position and advancing business development discussions,” said.

Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

B. Riley Financial

When company insiders — management, officers or any beneficial owners with more than 10% of a company's shares, as defined by the SEC — buy shares of their own company it's a bullish sign. That's because they believe the stock price will rise in the future.

News for Mountain Crest Acquisition Corp II Stock (BTTX)